JP2016517390A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517390A5
JP2016517390A5 JP2015555403A JP2015555403A JP2016517390A5 JP 2016517390 A5 JP2016517390 A5 JP 2016517390A5 JP 2015555403 A JP2015555403 A JP 2015555403A JP 2015555403 A JP2015555403 A JP 2015555403A JP 2016517390 A5 JP2016517390 A5 JP 2016517390A5
Authority
JP
Japan
Prior art keywords
buffer
heparinoid
acid
tris
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015555403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/013352 external-priority patent/WO2014171986A1/en
Publication of JP2016517390A publication Critical patent/JP2016517390A/ja
Publication of JP2016517390A5 publication Critical patent/JP2016517390A5/ja
Pending legal-status Critical Current

Links

JP2015555403A 2013-01-28 2014-01-28 ヘパリノイド、即時作用性麻酔薬、及び緩衝液を含む安定組成物 Pending JP2016517390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757592P 2013-01-28 2013-01-28
US61/757,592 2013-01-28
PCT/US2014/013352 WO2014171986A1 (en) 2013-01-28 2014-01-28 Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018152223A Division JP2019006783A (ja) 2013-01-28 2018-08-13 ヘパリノイド、即時作用性麻酔薬、及び緩衝液を含む安定組成物

Publications (2)

Publication Number Publication Date
JP2016517390A JP2016517390A (ja) 2016-06-16
JP2016517390A5 true JP2016517390A5 (enExample) 2017-03-02

Family

ID=51731742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555403A Pending JP2016517390A (ja) 2013-01-28 2014-01-28 ヘパリノイド、即時作用性麻酔薬、及び緩衝液を含む安定組成物
JP2018152223A Pending JP2019006783A (ja) 2013-01-28 2018-08-13 ヘパリノイド、即時作用性麻酔薬、及び緩衝液を含む安定組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018152223A Pending JP2019006783A (ja) 2013-01-28 2018-08-13 ヘパリノイド、即時作用性麻酔薬、及び緩衝液を含む安定組成物

Country Status (13)

Country Link
US (1) US20150359816A1 (enExample)
EP (1) EP2948154A4 (enExample)
JP (2) JP2016517390A (enExample)
KR (1) KR20160008496A (enExample)
CN (1) CN105263503A (enExample)
AU (2) AU2014254472A1 (enExample)
BR (1) BR112015018047A8 (enExample)
CA (1) CA2899636C (enExample)
IL (1) IL240194B (enExample)
MX (1) MX2015009696A (enExample)
SG (1) SG11201505853RA (enExample)
WO (1) WO2014171986A1 (enExample)
ZA (1) ZA201505814B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
CA3090767A1 (en) 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
CN111787915A (zh) 2017-04-12 2020-10-16 尤里根制药股份有限公司 注射器中包含局部麻醉剂、缓冲剂和糖胺聚糖的稳定性提高的制品
EP3400951B1 (de) * 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
EP3415163B1 (de) * 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
ES2968164T3 (es) * 2019-04-26 2024-05-08 Tcm Biotech Int Corp Composición farmacéutica para la prevención de infección urinaria recurrente
TWI887239B (zh) * 2019-05-17 2025-06-21 日商半導體能源研究所股份有限公司 發光元件、發光裝置、電子機器及照明裝置
AU2020315353A1 (en) 2019-07-18 2022-03-10 C. Lowell Parsons Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
CN115814099B (zh) * 2022-12-19 2024-04-26 成都蓉生药业有限责任公司 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法
MX2023012862A (es) * 2023-10-27 2023-11-09 Mar Mariana Guerrero Composicion topica de agentes esclerosantes en portadores acuosos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603695A (en) * 1995-06-07 1997-02-18 Erickson; Kim Device for alkalizing local anesthetic injection medication
SI1708722T1 (sl) * 2004-01-28 2014-10-30 The Regents Of The University Of California Nova intersticijska terapija za takojšnje simptome sprostitve in kronična terapija pri intersticijskem cistitisu
EP2839830B1 (en) * 2005-01-14 2019-05-15 Urigen, Inc. Kits and compositions for treating lower urinary tract disorders
WO2007073397A1 (en) * 2005-12-19 2007-06-28 Urigen, Inc. Kits and improved compositions for treating lower urinary tract discorders
US8357795B2 (en) * 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
ES2634505T3 (es) * 2009-08-13 2017-09-28 Lubris Llc Tratamiento de PRG4 para la cistitis intersticial
US20140194380A1 (en) * 2011-01-06 2014-07-10 Lowell C. Parsons Method of manufacturing composition comprising local anesthetic, heparinoid, and buffer
US9486747B2 (en) * 2014-08-12 2016-11-08 The Curators Of The University Of Missouri Nanocomposite membranes with advanced antifouling properties under visible light irradiation

Similar Documents

Publication Publication Date Title
JP2016517390A5 (enExample)
JP2004532217A5 (enExample)
ECSP088903A (es) Composiciones farmacéuticas de anticuerpo antagonista anti-cd40
EA200801776A1 (ru) Гидразиды миндальной кислоты
CA2438544A1 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
JP2012224636A5 (enExample)
NO20080357L (no) Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av samme
RU2012153786A (ru) Стабильные многодозовые композиции, содержащие антитело и консервант
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
JP2017061503A (ja) 局所麻酔剤、ヘパリノイド、及び緩衝剤を含む組成物を製造する方法
KR20160008496A (ko) 헤파리노이드, 급성 작용성 마취제 및 버퍼를 포함하는 안정한 조성물
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound
CA3064788A1 (en) Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
JP2017502278A5 (enExample)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
AR085059A1 (es) Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla
CN104402126B (zh) 一种油田专用杀菌缓蚀剂
NZ732509A (en) Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
NZ732509B2 (en) Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
Akhtardanesh et al. Evaluation of haematological and biochemical changes after short term tramadol usage in healthy dogs.
BR112013025105A2 (pt) sal de ácido benzoico de otamixaban
WO2009141786A3 (en) Anti-inflammatory compounds
Joseph et al. Role Of Caveolin-1 In Silica-Induced Injury In The Mouse Lung